<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0213-9111</journal-id>
<journal-title><![CDATA[Gaceta Sanitaria]]></journal-title>
<abbrev-journal-title><![CDATA[Gac Sanit]]></abbrev-journal-title>
<issn>0213-9111</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Salud Pública y Administración Sanitaria (SESPAS)]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0213-91112020000200007</article-id>
<article-id pub-id-type="doi">10.1016/j.gaceta.2019.02.009</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Evaluation of new medicines in Spain and comparison with other European countries]]></article-title>
<article-title xml:lang="es"><![CDATA[Evaluación de nuevos medicamentos en España y comparación con otros países europeos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espín]]></surname>
<given-names><![CDATA[Jaime]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,University of Granada Department of Applied Economics ]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Escuela Andaluza de Salud Pública  ]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto de Investigación Biosanitaria  ]]></institution>
<addr-line><![CDATA[Granada ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro de Investigación Biomédica en Red Epidemiología y Salud Pública  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<volume>34</volume>
<numero>2</numero>
<fpage>133</fpage>
<lpage>140</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S0213-91112020000200007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S0213-91112020000200007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S0213-91112020000200007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective To compare the use of health technology assessment (HTA) as a tool to support pricing and reimbursement (P&amp;R) of new medicines in Spain with England, Sweden, France and Germany.  Method For each country, the literature is used to identify the purpose and timing of the P&amp;R decision, the HTA and decision-making procedures used to generate evidence, and the criteria used to make decisions.  Results Results are presented as a summary of the HTA landscape for P&amp;R of new medicines in each country. Comparisons are made between Spain and other countries regarding the procedure and implementation of HTA.  Conclusions Based on these assessments, we made recommendations for how HTA might develop in Spain with the aim of improving governance and efficiency. Spain has made considerable progress in recent years, but still falls short of international standards in terms of independence of the HTA agencies and decision-making committees from political influence and industrial policy, the setting of prices of medicines in relation to health gain, improve the transparency of the process and results of the evaluation, and promote the participation of stakeholders. In common with other countries, Spain needs to clarify the role of cost-effectiveness criteria. Further progress needs to be made to coordinate effort across the various agencies, strengthen technical staff, and ensure equitable access to medicines between regions.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo Comparar el uso de la evaluación de tecnologías sanitarias (ETS) como instrumento para apoyar la fijación de precios y el reembolso de nuevos medicamentos en España con otros países europeos como Inglaterra, Suecia, Francia y Alemania.  Método Se realiza una revisión de la literatura para identificar, en cada país, el objetivo y la cronología de la decisión, los procedimientos para realizar la ETS y los criterios para tomar decisiones.  Resultados Se presenta una descripción narrativa de la situación en cada país y una comparación entre España y otros países sobre los procedimientos y la implementación de ETS.  Conclusiones Basándose en estas evaluaciones, se propone una serie de recomendaciones para mejorar el proceso. España ha avanzado significativamente en ETS en los últimos años, pero aún falta garantizar la independencia de las agencias de ETS, eliminar la influencia de la política económica e industrial de los comités de decisiones sanitarias, fijar precios basados en el valor terapéutico, mejorar la transparencia del proceso y de los resultados de las evaluaciones, y por último, aumentar la participación de los grupos de interés. Al igual que en otros países de su entorno, España tiene que clarificar el papel de la evaluación económica como criterio de decisión. Hace falta una mejor coordinación entre las diversas agencias que participan en ETS en España, fomentar el personal técnico y monitorizar la equidad de acceso a nuevos medicamentos entre las comunidades autónomas.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Health technology appraisal]]></kwd>
<kwd lng="en"><![CDATA[Health technology assessment]]></kwd>
<kwd lng="en"><![CDATA[Pricing and reimbursement]]></kwd>
<kwd lng="en"><![CDATA[Health policy]]></kwd>
<kwd lng="en"><![CDATA[Spain]]></kwd>
<kwd lng="es"><![CDATA[Evaluación de tecnología sanitaria]]></kwd>
<kwd lng="es"><![CDATA[Evaluación de la tecnología sanitaria]]></kwd>
<kwd lng="es"><![CDATA[Precio y reembolso]]></kwd>
<kwd lng="es"><![CDATA[Financiación]]></kwd>
<kwd lng="es"><![CDATA[España]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>European Communities</collab>
<article-title xml:lang=""><![CDATA[Council Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems]]></article-title>
<source><![CDATA[Official Journal of the European Communities]]></source>
<year>1988</year>
<volume>40</volume>
<page-range>9-12</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Tribunal de Cuentas</collab>
<source><![CDATA[Informe número 1185 del Tribunal de Cuentas]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>CNMC</collab>
<source><![CDATA[IPN/CNMC/005/15 Informe sobre el proyecto de Real Decreto Legislativo por el que se aprueba el texto refundido de la ley de garantías y uso racional de los medicamentos y productos sanitarios]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abellán Perpiñán]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Martínez]]></surname>
<given-names><![CDATA[FI]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Pérez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[El sistema sanitario público en España y sus comunidades autónomas: sostenibilidad y reformas]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Fundación BBVA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Lorenzo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejo-Torres]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Trujillo-Martín]]></surname>
<given-names><![CDATA[M Del Mar]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic evaluation seeks threshold to support decision-making]]></article-title>
<source><![CDATA[Rev Esp Salud Publica]]></source>
<year>2015</year>
<volume>89</volume>
<page-range>537-44</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llano-Señarís]]></surname>
<given-names><![CDATA[JE Del]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What health technology assessment system do we really need? A critical review of the current situation of health technology assessment in five European countries]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Llano-Señarís]]></surname>
<given-names><![CDATA[J Del]]></given-names>
</name>
<name>
<surname><![CDATA[Campillo-Artero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Health technology assessment and health policy today: a multifaceted view of their unstable crossroads]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Cham, Switzerland ]]></publisher-loc>
<publisher-name><![CDATA[Springer International Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abellán Perpiñán]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Pérez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cómo articular la cooperación en red de los recursos sobre conocimiento y evaluación en salud y servicios sanitarios en España. ¿Hacia un HispaNICE?]]></article-title>
<source><![CDATA[Gac Sanit]]></source>
<year>2016</year>
<volume>30</volume>
<page-range>14-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Políticas actuales de precios de medicamentos en Europa: panorama general]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Cham, Switzerland ]]></publisher-loc>
<publisher-name><![CDATA[Springer International Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Análisis y práctica de las políticas de precios y financiación de los medicamentos]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Cham, Switzerland ]]></publisher-loc>
<publisher-name><![CDATA[Springer International Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angelis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kanavos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries]]></article-title>
<source><![CDATA[Eur J Heal Econ]]></source>
<year>2017</year>
<volume>19</volume>
<page-range>123-52</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorenson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kanavos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Ensuring value for money in healthcare. European Observatory on Health Systems and Policies]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wittenauer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aden]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Priority medicines for Europe and the world. A public health approach to innovation]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berntgen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gourvil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving the contribution of regulatory assessment reports to health technology assessments. A collaboration between the European Medicines Agency and the European Network for Health Technology Assessment]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2014</year>
<volume>17</volume>
<page-range>634-41</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cleemput]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Franken]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European medicine reimbursement systems' legitimacy: five-country comparison and policy tool]]></article-title>
<source><![CDATA[Int J Technol Assess Health Care]]></source>
<year>2012</year>
<volume>4</volume>
<page-range>358-66</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicod]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kanavos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: a mixed methods study]]></article-title>
<source><![CDATA[Health Policy]]></source>
<year>2016</year>
<volume>120</volume>
<page-range>35-45</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mauskopf]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Walter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Birt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differences among formulary submission guidelines: implications for health technology assessment]]></article-title>
<source><![CDATA[Int J Technol Assess Health Care]]></source>
<year>2011</year>
<volume>27</volume>
<page-range>261-70</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schulte]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmaceutical pricing and reimbursement policies in the inand outpatient sector]]></source>
<year>2015</year>
<publisher-loc><![CDATA[United Kingdom ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad, Servicios Sociales e Igualdad</collab>
<source><![CDATA[Products flow chart pharmaceutical system in Spain in the inand out-patient sector]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>TLV</collab>
<source><![CDATA[Pharmaceutical pricing and reimbursement policies Sweden]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[The pharmaceutical system in France in the inand out-patient sector]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wenzl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paris]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Phamaceutical reimbursement and pricing in Germany]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad, Servicios Sociales e Igualdad</collab>
<source><![CDATA[Proyecto de RD por el que se regula la financiación y fijación de precios de medicamentos y productos sanitarios y su inclusión en la prestación farmacéutica del Sistema Nacional de Salud]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ubago Pérez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo Muñoz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Banqueri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía metodológica para la evaluación de la eficacia y la seguridad de nuevos fármacos: implementación de las recomendaciones de EUnetHTA]]></article-title>
<source><![CDATA[Gac Sanit]]></source>
<year>2017</year>
<volume>31</volume>
<page-range>336-41</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<collab>Ministerio de Sanidad, Servicios Sociales e Igualdad</collab>
<article-title xml:lang=""><![CDATA[Real Decreto Legislativo 1/2015, de 24 de julio, por el que se aprueba el texto refundido de la Ley de garantías y uso racional de los medicamentos y productos sanitarios]]></article-title>
<source><![CDATA[BOE]]></source>
<year>2015</year>
<volume>177</volume>
<page-range>62935-3030</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>Genesis</collab>
<source><![CDATA[Guía de evaluación económica e impacto presupuestario en los informes de evaluación de medicamentos. Guía práctica asociada al programa MADRE 4.0]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lauterbach]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McDonough]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Seeley]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Germany's model for medicine price regulation could work in the US]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruof]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Schulenburg]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation]]></article-title>
<source><![CDATA[Eur J Heal Econ]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>577-89</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caro]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nord]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Siebert]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The efficiency frontier approach to economic evaluation of health-care interventions]]></article-title>
<source><![CDATA[Health Econ]]></source>
<year>2010</year>
<volume>19</volume>
<page-range>1117-27</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le Pen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Priol]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lilliu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of 'medical service rendered' by reimbursable medicines in France]]></article-title>
<source><![CDATA[Eur J Heal Econ]]></source>
<year>2003</year>
<volume>4</volume>
<page-range>30-6</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<collab>Haute Autorité de Santé</collab>
<source><![CDATA[Pricing and reimbursement of medicines and HTA policies in France]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="book">
<collab>Haute Autorité de Santé</collab>
<source><![CDATA[Choices in methods for economic evaluation: a methodological guide]]></source>
<year>2012</year>
<publisher-name><![CDATA[Haute Aut Sante]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stefani]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of cost-effectiveness evaluation in France and future path for cost containment]]></article-title>
<source><![CDATA[ICON Briefing]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toumi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Motrunich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Millier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment]]></article-title>
<source><![CDATA[J Mark Access Heal Policy]]></source>
<year>2017</year>
<volume>5</volume>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rumeau-Pichon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Harousseau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of cost-effectiveness assessments in France by the French National Authority for Health (HAS)]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2014</year>
<volume>17</volume>
<page-range>A323-686</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Svensson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nilsson]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Arnberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>1229-36</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="">
<collab>TLV</collab>
<source><![CDATA[General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2)]]></source>
<year>2003</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="book">
<collab>OECD</collab>
<source><![CDATA[New Health Technologies: Managing Access, Value and Sustainability]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Paris ]]></publisher-loc>
<publisher-name><![CDATA[OECD Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="">
<collab>NICE</collab>
<source><![CDATA[About NICE: topic selection]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="">
<collab>NICE</collab>
<source><![CDATA[NICE gets go-ahead to fast-track more medicine approvals]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="">
<collab>NICE</collab>
<source><![CDATA[Guide to the methods of technology appraisal]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rovira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antoñanzas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>1995</year>
<volume>8</volume>
<page-range>245-52</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Propuesta de colaboración para la elaboración de los informes de posicionamiento terapéutico de los medicamentos. Documento aprobado por la Comisión Permanente de Farmacia del SNS, 21 de mayo de 2013]]></source>
<year>2013</year>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Jönsson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Key principles for the improved conduct of health technology assessments for resource allocation decisions]]></article-title>
<source><![CDATA[Int J Technol Assess Health Care]]></source>
<year>2008</year>
<volume>24</volume>
<page-range>244-58</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="">
<collab>Economist</collab>
<article-title xml:lang=""><![CDATA[Spanish public money could be much better spent]]></article-title>
<source><![CDATA[]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciani]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Jommi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of health technology assessment bodies in shaping medicine development]]></article-title>
<source><![CDATA[Medicine Des Devel Ther]]></source>
<year>2014</year>
<volume>8</volume>
<page-range>2273-81</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Bastida]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antoñanzas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A proposed guideline for economic evaluation of health technologies]]></article-title>
<source><![CDATA[Gac Sanit]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>154-70</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La Guía de Génesis-SEFH propone umbrales de referencia de 21.000 euros por AVAC]]></article-title>
<source><![CDATA[Farmacia Hospitalaria]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rovira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ten years of cost-effectiveness threshold]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2013</year>
<volume>37</volume>
<page-range>85-7</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallejo-Torres]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[García-Lorenzo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano-Aguilar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating a costeffectiveness threshold for the Spanish NHS]]></article-title>
<source><![CDATA[Health Econ]]></source>
<year>2018</year>
<volume>27</volume>
<page-range>746-61</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barham]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single technology appraisals by NICE: are they delivering faster guidance to the NHS?]]></article-title>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>1037-43</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catalá-López]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[García-Altés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic evaluation of healthcare interventions during more than 25 years in Spain (1983-2008)]]></article-title>
<source><![CDATA[Rev Esp Salud Publica]]></source>
<year>2010</year>
<volume>84</volume>
<page-range>353-69</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ximenez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La disparidad autonómica explica la inequidad de acceso a la innovación terapéutica]]></article-title>
<source><![CDATA[Acta Sanitaria]]></source>
<year>2016</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
